FGN FG Q1 2026 earnings miss estimates by 21 as costs rise shares decline marginally What Wall Street expects from Kyverna Therapeutics KYTX this quarter KYTX Q4 2025 Kyverna Therapeutics Beats EPS Estimates with Zero Revenue Absci Corp ABSI Strong Analyst Consensus and Novel Pipeline Drive Compelling Upside Potential DUO Fangdd climbs 473 percent in todays session despite posting a wide Q2 2021 EPS miss Consumer Prices Surge to 38 Annually in April Exceeding Expectations SpaceX Targets Nearly 2 Trillion Valuation in IPO Betting on Musks RocketstoAI Vision Japans Megabanks Enjoy Record Profits but Analysts Warn of Slowing Growth Amid Rising Risks Hitachi Secures Contract for Mexican Railway Signaling System Ubisoft Shares Decline as Assassins Creed Developer Warns of Continued Losses Sensex Dips 142 Points Nifty Holds Above 23900 as Mid and SmallCaps Shine Ebola Outbreak in DR Congo Red Cross Casualties Raise Regional Health and Economic Risks